Search

A recent study conducted at Henan University in Luoyang, People's Republic of China, focused on the construction of compound protein lipid materials to potentially alleviate alcoholic fatty liver disease (AFLD). The study identified 21 core targets for epigallocatechin gallate (EGCG) that could improve the therapeutic effect of AFLD, particularly in cancer and prostate cancer pathways. By simulating the formation of composite lipid materials, the research provided new insights into addressing AFLD and developing products to mitigate the effects of alcohol. The study was funded by various organizations and has been peer-reviewed, offering valuable contributions to the field of bioinformatics and biotechnology. [Extracted from the article]

University of Calabar researchers conducted a study to assess the diagnostic accuracy of radiological and histological findings in diagnosing non-alcoholic fatty liver disease stages among patients. The study included 109 participants, with ultrasound showing a sensitivity of 90.4% and a specificity of 72.5%. The research concluded that ultrasound findings were significant in detecting advanced stages of fatty liver, potentially reducing the need for invasive procedures like liver biopsy in the future. [Extracted from the article]

A study conducted at Wannan Medical College in Wuhu, People's Republic of China, focused on developing fluorescent probes for visualizing lipid droplets (LDs) to diagnose and treat related diseases. The researchers designed five fluorescent molecules, with one, WZX5, showing promise in targeting LDs and visualizing the process of lipophagy. The study concluded that probe WZX5 could be a valuable tool for diagnosing LDs-associated diseases and studying lipophagy processes. The research was funded by various organizations and has been peer-reviewed. [Extracted from the article]

A recent clinical trial conducted at Qazvin University of Medical Sciences investigated the effects of ellagic acid on patients with non-alcoholic fatty liver disease (NAFLD). The study found that ellagic acid supplementation led to significant reductions in various biochemical factors associated with NAFLD, such as insulin resistance, liver enzymes, and oxidative stress markers. The researchers concluded that ellagic acid could be used as a supplemental therapy to reduce complications of NAFLD due to its antioxidant and anti-inflammatory properties. [Extracted from the article]

Researchers at the First Affiliated Hospital of China Medical University conducted a study on the safety and efficacy of dietary epigallocatechin gallate (EGCG) supplementation for managing obesity and non-alcoholic fatty liver disease (NAFLD). While EGCG has been associated with positive effects on health parameters in individuals with obesity and NAFLD, there are also reports suggesting potential hepatotoxicity. The study provides a comprehensive review of clinical findings on the effects of EGCG in treating obesity and NAFLD, focusing on treatment duration and dosage levels. For more information, the research article "The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent Updates" can be accessed for free. [Extracted from the article]

A recent study from the University of Turin explores the role of the gut-liver axis in Non-Alcoholic Fatty Liver Disease (NAFLD) and the potential therapeutic effects of prebiotics in treating the condition. The research highlights the impact of gut microbiota on liver health and emphasizes the importance of maintaining a healthy intestinal barrier to prevent the progression of NAFLD. By focusing on dietary interventions like prebiotics, the study aims to address the underlying mechanisms of NAFLD and improve patient outcomes. [Extracted from the article]

Researchers from Fuzhou University in China have highlighted the potential of marine natural products in managing non-alcoholic fatty liver disease (NAFLD). With a global prevalence of 32.4%, NAFLD is a common chronic liver condition. The study explores how marine bioactive substances like polysaccharides and polyphenols can benefit liver health by addressing metabolic dysfunction. This research establishes a connection between marine compounds and the potential management of NAFLD, offering new avenues for therapeutic development. [Extracted from the article]

A recent study conducted by researchers at Hamad Bin Khalifa University in Qatar has produced a large ultrasound image dataset of Non-Alcoholic Fatty Liver Disease (NAFLD) from Saudi hospitals. The dataset includes 10,352 high-resolution ultrasound images from 384 patients, each meticulously annotated with NAFLD Activity Score (NAS) fibrosis staging and steatosis grading based on liver biopsy results. This resource aims to support the development of AI algorithms for accurate NAFLD diagnosis and staging, providing a valuable tool for researchers in the field of medical imaging. For more information, the full article can be accessed for free at https://doi.org/10.1016/j.dib.2024.111266. [Extracted from the article]

Recent studies from Nantong University have explored the associations between exposure to brominated flame retardants (BFRs) and non-alcoholic fatty liver disease (NAFLD) in the general population. The research, which included 4110 adults from the National Health and Nutrition Examination Survey (NHANES), found that specific concentrations of BFRs are linked to an increased risk of NAFLD, with certain compounds like PBB153, PBDE28, PBDE209, and PBDE153 posing potential risk factors. Additionally, the study suggests that oxidative stress and chronic inflammation may mediate the effects of BFR exposure on NAFLD development, with men showing higher serum BFR concentrations and a more prominent association with NAFLD compared to women. [Extracted from the article]

Researchers at Tehran University of Medical Sciences conducted a study on children with non-alcoholic fatty liver disease (NAFLD) in Iran. The study found that early detection and intervention are crucial to prevent long-term complications of NAFLD. Most children with NAFLD in the study were male, had a family history of the disease, and showed elevated levels of liver enzymes and lipids. The research emphasizes the importance of considering family history and metabolic markers in the diagnosis and management of NAFLD in children. [Extracted from the article]

Researchers at Wuxi No.2 People's Hospital conducted a study on the association between biological aging, healthy eating index-2015, and non-alcoholic fatty liver disease (NAFLD) in the United States population using data from the NHANES database. The study found that biological aging was positively correlated with NAFLD prevalence, while the healthy eating index-2015 was negatively correlated with NAFLD risk. The research concluded that the prevalence of NAFLD increases with biological aging but can be mitigated by a healthy diet. [Extracted from the article]

Researchers from the Medical University of Lublin conducted a study on non-alcoholic fatty liver disease (NAFLD), focusing on microRNAs, serological markers of liver fibrosis, and hematological parameters. The study included 207 participants, with higher concentrations of miR-126-3p and miR-1-3p and lower levels of miR-197-3p observed in the NAFLD group. The research suggests significant correlations between miRNA molecules and hematological markers in NAFLD, indicating inflammation as a potential factor and offering new diagnostic possibilities. [Extracted from the article]

A study conducted in the U.S. from 1998 to 2020 analyzed hospitalization data of pediatric patients with Non-Alcoholic Fatty Liver Disease (NAFLD). The research identified an increasing trend in hospitalization rates for NAFLD among pediatric populations and highlighted significant risk factors associated with mortality. Factors such as coagulopathy, age, diabetes, and obesity were found to impact mortality rates, while sex, race/ethnicity, and certain infections were not significantly associated with mortality. Further research is recommended to gather more data on this patient population. [Extracted from the article]

A patent application titled "Hepatic Organoids" was published online by inventors from the Netherlands, focusing on modeling non-alcoholic fatty liver disease (NAFLD) in human hepatocyte organoids. The application highlights the importance of genetic and diet-driven factors in lipid accumulation and steatosis, as well as the potential role of FADS2 in regulating lipid metabolism. The organoids described in the patent aim to provide a model system for studying lipid homeostasis and related diseases, offering insights into NAFLD, NASH, and other fatty liver disorders. [Extracted from the article]

Researchers at Theagenio Cancer Hospital in Thessaloniki, Greece, have published a report on the gut microbiome's role in non-alcoholic fatty liver disease (NAFLD). The study highlights how gut dysbiosis, or the imbalance of gut bacteria, can impact liver health through various pathways. The research suggests that interventions such as probiotics, prebiotics, and even fecal microbiota transplantation (FMT) may hold promise in preventing and managing NAFLD. For more information, the full article can be accessed in Frontiers in Gastroenterology. [Extracted from the article]

A recent study conducted by researchers from Iran University for Medical Sciences explored the association between heavy metal exposure and non-alcoholic fatty liver disease (NAFLD). The systematic review found a positive relationship between arsenic, cadmium, iron, lead, mercury, and fatty liver disease, while a negative association was observed with zinc and copper. The study also highlighted magnetic resonance imaging (MRI) as a sensitive diagnostic method for NAFLD. This research provides valuable insights into the impact of heavy metal exposure on liver health and disease progression. [Extracted from the article]

The article discusses recent advances in understanding alcoholic fatty liver disease, emphasizing the complex inter-organ metabolic interactions involved in its pathogenesis. Researchers from Gannan Medical University in China highlight the progression of non-alcoholic fatty liver disease (NAFLD) and its association with metabolic disorders driven by overnutrition. The study underscores the importance of investigating inter-organ communication mechanisms to deepen our understanding of NAFLD progression. [Extracted from the article]

Researchers at Capital Medical University in Beijing conducted a study on the association between the neutrophil-to-high-density lipoprotein cholesterol ratio (NHR) and non-alcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD). The study, based on data from the National Health and Nutrition Examination Survey (NHANES) 2017-2020, found a positive correlation between NHR levels and the risk of NAFLD/MASLD, particularly in certain subgroups. The researchers concluded that NHR could potentially serve as a marker for these conditions and lowering NHR levels may help reduce their incidence. [Extracted from the article]

A patent application titled "Quantitative Systems Pharmacology Methods For Identifying Therapeutics For Disease States" was published online by inventors GOUGH, Albert H.; STERN, Andrew Michael; TAYLOR, Douglas Lansing. The application focuses on developing a device integrating clinical data, public databases, and human experimental models to identify drugs for non-alcoholic fatty liver disease (NAFLD) by deriving molecular signatures, predicting drugs, and optimizing therapeutic regimens. The method involves analyzing RNA sequencing data, identifying differentially expressed genes, and prioritizing drugs for experimental testing to normalize gene expression signatures associated with specific disease states. The application aims to address the complexity and patient heterogeneity of NAFLD to develop effective treatments. [Extracted from the article]

A recent study conducted by the Karolinska Institute explored the relationship between loneliness, social isolation, and the risk of non-alcoholic fatty liver disease (NAFLD). The study, which included over 400,000 participants from the UK Biobank, found that both loneliness and social isolation were independently associated with an increased risk of NAFLD. The research also highlighted the role of lifestyle, depression, and inflammatory factors as potential mediators of this association. This study underscores the importance of addressing loneliness and social isolation in the prevention and management of NAFLD. [Extracted from the article]

Researchers at the First Affiliated Hospital of Anhui Medical University in China conducted a study on American adolescents, finding a positive correlation between weight-adjusted waist index (WWI) and non-alcoholic fatty liver disease (NAFLD). The study, based on National Health and Nutrition Examination Survey data, revealed that WWI was significantly associated with NAFLD, particularly in male participants aged 16 and older. The findings suggest that WWI could serve as a cost-effective method for identifying hepatic steatosis, emphasizing the importance of monitoring individuals with a WWI below 10.65. [Extracted from the article]

Researchers at Islamic Azad University conducted a study on the relationship between anthropometric indices and non-alcoholic fatty liver disease (NAFLD) in adults. The study, based on data from about 10,000 individuals, found that waist-to-height ratio (WHtR) and body mass index (BMI) were the most accurate predictors of NAFLD in both men and women. The research suggests that these indices could be practical and accessible tools for early screening of NAFLD, while other indices like body shape index (ABSI) showed minor effectiveness in identifying the disease. [Extracted from the article]

A recent study conducted at Hashemite University in Jordan found that there is a low level of awareness about non-alcoholic fatty liver disease (NAFLD) among parents of overweight and obese children. The research highlighted the need for effective awareness programs by health authorities to address this issue. The study showed that higher education levels, income levels, and working in the medical field were associated with higher levels of NAFLD knowledge among participants. This information is important for understanding and addressing the prevalence of NAFLD in children globally. [Extracted from the article]

Researchers from Nanchang University have conducted a study on alcoholic fatty liver disease, focusing on the role of the adipokine Omentin-1 in preserving autophagy through the AMPKa/mTOR signaling pathway. The study involved feeding mice a high-fat diet to induce nonalcoholic fatty liver disease and treating them with Omentin-1, which resulted in reduced weight gain, improved glucose homeostasis, and decreased hepatic lipid accumulation. The research suggests that Omentin-1 could be a potential therapeutic agent for non-alcoholic fatty liver disease by preserving autophagy through the AMPKa/mTOR pathway. [Extracted from the article]

A recent study conducted at Ningbo Medical Center Lihuili Hospital in China explored the prevalence and prognostic significance of malnutrition in patients with Non-Alcoholic Fatty Liver Disease (NAFLD). The study, which included 3908 participants, found that malnutrition is a common comorbidity in NAFLD patients and is closely associated with poor prognosis and higher mortality. The research suggests that three nutrition assessment tools could be used to predict nutritional status and mortality among NAFLD patients. For more information, readers can refer to the International Journal for Vitamin and Nutrition Research. [Extracted from the article]

A recent study conducted at Tabriz University of Medical Sciences in Iran explored the effects of combining aerobic exercise with whole-body vibration (WBV) training on patients with non-alcoholic fatty liver disease (NAFLD). The randomized clinical trial involved 32 patients with grade 1 and 2 NAFLD, comparing the effects of the combined exercise regimen with aerobic exercise alone. The results showed that the group undergoing aerobic exercises with WBV experienced significant reductions in alanine aminotransferase (ALT) and triglyceride levels, suggesting that this combined method may be more effective for patients with NAFLD. [Extracted from the article]

Researchers in Xiaogan, China, conducted a study to investigate the influencing factors of postoperative urinary tract infection in benign prostatic hyperplasia (BPH) patients with non-alcoholic fatty liver disease (NAFLD). The study analyzed clinical data from 159 patients and identified factors such as operation time, history of diabetes mellitus, and abnormal liver function as independent influencing factors for postoperative urinary tract infection. A prediction model based on these factors was established, showing promise in predicting postoperative urinary tract infection in BPH patients with NAFLD. [Extracted from the article]

Recent research from the Affiliated Hospital of Hangzhou Normal University focuses on the association between the triglyceride to high-density lipoprotein cholesterol ratio and type 2 diabetes mellitus in individuals with non-alcoholic fatty liver disease (NAFLD). The study, conducted on 4,769 NAFLD patients, found that a higher TG/HDL-C ratio was positively associated with T2DM, indicating it could be a better predictor of diabetes risk than individual lipid parameters. Clinicians are advised to consider individuals with high triglyceride and low HDL-C levels when assessing T2DM risk in NAFLD cohorts. [Extracted from the article]

A recent study conducted at the Affiliated Hospital of Southeast University in China explored the relationship between vitamin D deficiency, insulin resistance, and non-alcoholic fatty liver disease (NAFLD). The research, based on data from the National Health and Nutrition Examination Survey (NHANES) and gene expression datasets, found that increased levels of vitamin D were associated with reduced insulin resistance and improved NAFLD status. The study identified specific genes involved in the insulin resistance pathway that were affected by changes in vitamin D levels. This research suggests that vitamin D may play a role in improving NAFLD by reducing insulin resistance. [Extracted from the article]

A patent application has been submitted for a compound aimed at treating non-alcoholic fatty liver disease (NAFLD) and related conditions. NAFLD affects a significant portion of the global population, with a high prevalence in developed nations like the United States. The compound targets hepatic steatosis and inflammation associated with NAFLD, offering potential therapeutic benefits for patients. The lack of FDA-approved therapies for NAFLD underscores the urgent need for effective treatments to address this growing health concern. [Extracted from the article]

Researchers at the University of Medicine and Pharmacy Craiova have published new findings on non-alcoholic fatty liver disease (NAFLD), highlighting its global impact as the main cause of chronic liver disease. The study emphasizes the importance of recognizing NAFLD as a key diagnostic factor for various conditions, including metabolic syndrome, insulin resistance, diabetes, and other health disorders. The researchers recommend increased awareness, collaboration among healthcare professionals, and screening for individuals at risk of NAFLD to address this growing public health challenge. [Extracted from the article]

Researchers from Queensland University of Technology conducted a parallel randomized trial to assess a community-based fibrosis assessment service for suspected non-alcoholic fatty liver disease (NAFLD). The trial aimed to reduce the time to diagnosis of high-risk NAFLD and improve patient outcomes. While the intervention did not conclusively demonstrate a faster time to diagnosis, it significantly reduced the time to FibroScan by almost one year. The LOCATE model shows potential for impact in reducing waiting times for patients at high risk of severe liver disease due to NAFLD, but further research with a larger sample size and longer follow-ups is needed. [Extracted from the article]

Researchers from Mashhad University of Medical Sciences conducted a randomized controlled trial to investigate the therapeutic effects of flaxseed oil on Non-Alcoholic Fatty Liver Disease (NAFLD). The study involved 60 NAFLD patients who were assigned to either a flaxseed oil capsule or a placebo group for 2 months. Results showed significant improvements in liver enzymes and metabolic parameters in the flaxseed oil group compared to the placebo group, suggesting that flaxseed oil may be a promising intervention for NAFLD. This research was peer-reviewed and provides valuable insights into potential treatments for liver diseases. [Extracted from the article]

A recent study conducted at King Faisal University in Saudi Arabia examined the prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Saudi adults and its relationship with obesity and metabolic health. The study found a high prevalence of NAFLD in individuals categorized as 'Overweight' and 'Obese,' with significant associations between NAFLD and higher BMI categories. Additionally, the research highlighted the importance of targeted public health interventions and early detection strategies for NAFLD in individuals with high BMI to mitigate its impact in Saudi Arabia. [Extracted from the article]

A study from Tabriz University of Medical Sciences explored the relationship between copper status, abdominal obesity indices, and liver function in patients with non-alcoholic fatty liver disease (NAFLD). The research found that low copper intake was associated with an increased likelihood of NAFLD, after adjusting for potential confounders. The study involved 80 overweight/obese patients with NAFLD and 80 healthy controls, highlighting differences in dietary intake and serum levels of liver aminotransferases, ferritin, copper, and ceruloplasmin between the two groups. The findings suggest a potential link between copper intake and the development of NAFLD. [Extracted from the article]

A recent study conducted by the Shandong Academy of Agricultural Sciences in China explored the use of medium-chain triglycerides (MCT) in alleviating non-alcoholic fatty liver disease (NAFLD). The research found that MCT supplements were more effective in improving weight gain, blood lipids, and hepatic lipid accumulation compared to traditional long-chain vegetable oils. The study highlighted the potential of MCT in treating NAFLD and provided new evidence for its application in this condition. [Extracted from the article]

A study conducted at Taichung Veterans General Hospital in Taiwan examined the association between metabolic dysfunction-associated fatty liver disease (MAFLD) and carotid atherosclerosis. The research found that MAFLD patients had a higher prevalence of carotid atherosclerosis compared to non-alcoholic fatty liver disease (NAFLD) patients. This suggests that MAFLD may be a significant risk factor for cardiovascular complications. The study involved a retrospective cohort design with 11,194 participants and was published in Nutrition, Metabolism and Cardiovascular Diseases. [Extracted from the article]

A study conducted at Jeonbuk National University in South Korea explored the effects of fermented gold kiwifruit on mice with high-fat diet-induced obesity and hepatic steatosis. The research found that fermented gold kiwifruit supplementation significantly reduced levels of liver enzymes, cholesterol, triglycerides, and glucose in the mice. Additionally, the study suggested that fermented gold kiwifruit could potentially reduce the severity of non-alcoholic fatty liver disease by inhibiting fat synthesis, promoting fat breakdown, and suppressing inflammation in obese mice. [Extracted from the article]

Researchers from Shanghai University of Traditional Chinese Medicine conducted a study on the potential of puerarin in alleviating non-alcoholic fatty liver disease (NAFLD) using network pharmacology and experimental analysis methods. The study identified 189 target genes related to NAFLD and found that puerarin may modulate inflammatory pathways and regulate oxidative stress, thereby reducing liver inflammation and slowing the progression of NAFLD. The research suggests that puerarin could be developed as a potential treatment for NAFLD, either as an oral medication or in combination with other treatments to improve liver health in patients. [Extracted from the article]

Researchers at Nanjing Drum Tower Hospital in China conducted a study on the association between impaired sensitivity to thyroid hormone and non-alcoholic fatty liver disease (NAFLD) in diabetic individuals. The study included over 26,000 participants from a health screening program and over 8,000 hospitalized patients with type 2 diabetes. The findings indicated that impaired sensitivity to thyroid hormone was linked to an increased risk of developing NAFLD but a reduced risk of advanced fibrosis, specifically in diabetic individuals. The researchers suggest the need for further stratified studies on NAFLD based on diabetic status in the future. [Extracted from the article]

A study conducted in Beijing, China, explored the diagnostic value of the computed tomography (CT) liver-to-spleen attenuation ratio in patients with non-alcoholic fatty liver disease (NAFLD) and atherosclerotic plaque (AP). The research found that the CT L/S attenuation ratio was significantly reduced in NAFLD patients with AP and correlated with blood lipid levels. The study concluded that the CT L/S attenuation ratio has a high predictive value for NAFLD patients with AP. [Extracted from the article]

Researchers in Guangzhou, China, have conducted a study on the relationship between Non-Alcoholic Fatty Liver Disease (NAFLD) and myocardial infarction (MI). Through bioinformatics and machine learning, they identified Thrombospondin 1 (THBS1) as a potential biomarker for NAFLD-related MI. The study also highlighted the role of CD8+ T cells and neutrophils in distinguishing NAFLD/MI patients from healthy individuals. This research provides valuable insights into the immune features of NAFLD and MI patients. [Extracted from the article]

The patent application titled "Methods Of Treating Diseases Associated With Senescent Cell Accumulation" discusses the discovery of compounds that can address liver diseases and age-related conditions by targeting senescent cells. These compounds have the potential to treat diseases such as alcohol-induced liver disease, non-alcoholic fatty liver disease, and liver cancer. The application outlines methods for degrading specific proteins and killing senescent cells to address various health issues. The inventors aim to develop treatments that can reduce toxicity and improve clinical outcomes for patients with these conditions. [Extracted from the article]

A clinical trial, NCT06718842, is being conducted by Cairo University to study the response of liver enzymes in children with phenylketonuria (PKU) and non-alcoholic fatty liver. The trial involves a walking program for PKU children with fatty liver, where participants will be randomly assigned to either a walking program group or a waitlisted group. The study aims to assess the impact of the walking program on liver enzymes and metabolic complications associated with PKU. [Extracted from the article]

Researchers from the Department of Kayachikitsa in New Delhi, India, have explored the potential role of Ayurveda interventions in managing Grade II Non Alcoholic Fatty Liver Disease (NAFLD). They presented a case study of a 59-year-old male who experienced relief from symptoms and improvement in liver health through Ayurveda-based therapies. The study highlights the effectiveness of individualized Ayurveda treatment in addressing NAFLD and emphasizes the importance of integrating traditional medicine into the clinical management of liver disorders. The research offers valuable insights into alternative approaches for managing liver conditions. [Extracted from the article]

Researchers from Ahvaz conducted a study on Non-Alcoholic Fatty Liver Disease (NAFLD) to investigate the correlation between liver size, liver enzymes, and the progression of fatty liver in patients. The study included 100 patients and found that as NAFLD progresses, liver enzymes and size increase. The research concluded that increasing liver size suggests NAFLD grade II, while elevated AST levels and BMI suggest progression to NAFLD grade II-III and cirrhosis. The study provides valuable insights into the progression of NAFLD and its impact on liver health. [Extracted from the article]